Macular Degeneration is an eye condition that occurs when aging causes damage to the macula. The macula is part of the retina (the light-sensitive tissue at the back of the eye that controls sharp, straight-ahead vision.
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in adults over 55. It is expected to affect 288 million people worldwide by the year 2040.
The exact cause of macular degeneration is not exactly known, but research indicated it’s a combination of genetic and environmental factors. These risk factors include:
No. However, the last decade has made significant breakthroughs in treatment options. Today, some medications help control and slow the progression of AMD and, in some cases, may even improve vision.
The two forms of macular degeneration are called dry and wet macular degeneration. Both affect the macula, which is part of the retina of your eye. Their differences lie in the speed of the onset of the disease and its severity.
Dry AMD is the less severe early stage and is more common. Eighty percent of AMD patients have a dry form, which gradually worsens over the years.
In the dry stage, tiny yellow deposits of metabolic waste, known as ¨drusen¨, form in the macula. At first, they have little effect on vision. However, as the disease progresses and drusen accumulate, they obstruct the flow of nutrients and oxygen to the macula.
The only treatment available for dry AMD is a pill called AREDS2 formula. AREDS2 is a mixture of antioxidant supplements and two visual pigments (lutein and zeaxanthin) essential for retinal function.
AREDS2 has been shown to reduce the risk of dry AMD progressing to the advanced Wet form by 25% per year.
Wet macular degeneration (Wet AMD) is the more advanced form of this disease, and about 20% of Dry AMD patients will progress to it. Also, If the condition has quickly appeared over weeks to months, it too is wet AMD.
The wet stage of AMD is aggressive and requires urgent treatment by a retinal specialist to prevent progressive vision loss. If wet AMD is left untreated, blood or liquid build-up in the retina leads to scarring, which can cause irreversible vision loss.
Eyes with wet AMD have increased production of a Vascular Endothelial Growth Factor (VEGF) protein. This protein triggers the growth of new blood vessels in the retina. Too much VEGF in the eye leads to the creation of fragile malformed blood vessels. These vessels leak, causing damage to the macula and surrounding retina that eventually leads to central vision loss.
If you get wet AMD in one eye, you’ll have a 20% chance of developing it in your other eye within five years.
Once AMD progresses to the wet form, pills are no longer an acceptable treatment option. Instead, medications must be placed directly within the eye to help control the disease at its source. Luckily, injectable medications have revolutionized the treatment for Wet AMD.
Although they sound scary, intraocular injections are quick, painless, safe, and effective in slowing disease progression. And in some cases, restoring some of the lost vision, Known as anti-VEGF medications, which include Lucentis and Eyelea.
In some cases, a laser treatment called photodynamic therapy may be effective. Our retina specialist will recommend the option(s) best suited for your situation.
No, but simple lifestyle changes can decrease your risk of developing it. These include eating plenty of dark green leafy vegetables, salmon, and other cold-water fish (for their omega-3 fatty acids).
It's also essential to exercise and avoid high blood pressure and high cholesterol. Wear sunglasses that provide 100 percent UV protection and protect your eyes from visible radiation and blue light. Lastly, if you smoke, stop!
We can’t overstate the importance of getting an annual eye exam to screen for AMD and other eye health conditions that can threaten your vision and quality of life.
Schedule your consultation today with our internationally recognized retina specialists
The AGEI staff includes a highly skilled Stanford-trained retina specialist, Dr. Svetlana Pilyugina (or “Dr. P”, as she is known to her patients). Dr. P is an ophthalmologist with fellowship training and board certification in diseases and surgery of the vitreous and retina.
Dr. Pilyugina has extensive experience treating macular degeneration, retinal detachment, and diabetic retinopathy, having treated thousands of patients for over a decade.
As a member of an elite group of only 3000 vitreoretinal specialists in the United States, Dr. Pilyugina brings to AGEI a unique skill set in the treatment and surgery of retinal disease. Her academic credentials include numerous research papers, conference presentations, medical publications, and ophthalmology clinical trials.
We are conveniently located for patients throughout Southern California and the Los Angeles area in or near Beverly Hills, Santa Monica, West Los Angeles, West Hollywood, Culver City, Hollywood, Venice, Marina del Rey, Malibu, Manhattan Beach, and Downtown Los Angeles.
Yes, macular degeneration can have a hereditary component. However, having a genetic predisposition to the disease does not necessarily mean an individual will develop macular degeneration. Lifestyle factors such as smoking, diet, and sun exposure can also increase the risk of developing the disease.
The early warning signs of macular degeneration may include:
No, it cannot be reversed. However, early detection and treatments can slow or pause the progression of the disease, allowing you to maintain your lifestyle during treatments.
Macular degeneration can cause blurry or distorted vision in the center of the visual field. Usually, you're still able to use your peripheral vision. You can learn how to use your side vision to help you do things with the help of a vision rehabilitation specialist who can teach you how this works.
No specific vitamin or nutritional supplement has been proven to cure or prevent macular degeneration. However, a large study by the National Eye Institute, called AREDS (Age-Related Eye Disease Study), found that certain vitamins and nutrients like beta-carotene and vitamin E may protect the eyes in some people.
Wet (exudative) macular degeneration is generally considered more severe and can progress faster than dry (atrophic)macular degeneration.
In general, dry macular degeneration can take years or even decades to progress to the more advanced stages, where central vision loss becomes more noticeable.
Wet macular degeneration can progress rapidly and cause severe vision loss in weeks or months if left untreated.
Macular degeneration is typically diagnosed through a comprehensive eye exam that may include the following tests:
Foods that should be avoided or limited include:
Most people with macular degeneration do not go completely blind. Still, they may experience significant low vision, making it difficult or virtually impossible to perform everyday activities like reading, driving, and recognizing faces.
Yes, there are two forms of Wet AMD: occult and classic.
Occult wet macular degeneration is when new blood vessels grow less, and their leakage is less evident and is associated with less severe vision loss. Classic wet macular degeneration is when blood vessels and scars are clearly visible on the retina and usually results in more severe vision loss.
Yes, a person can have both glaucoma and macular degeneration. Although these are two different eye conditions, they can coincide, especially in older adults.
Research Sources:
AREDS 2 Supplements for Age-Related Macular Degeneration (AMD) | National Eye Institute | https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration/nutritional-supplements-age-related-macular-degeneration
Age-Related Macular Degeneration (AMD) | National Eye Institute | https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration
Vision Loss, Central - American Academy of Ophthalmology | https://www.aao.org/eye-health/symptoms/vision-loss-central
Ocular nutritional supplements: are their ingredients and manufacturers' claims evidence-based? PubMed | https://pubmed.ncbi.nlm.nih.gov/25458196
Dietary fatty acid intake, plasma fatty acid levels, and the risk of age-related macular degeneration (AMD): a dose-response meta-analysis of prospective cohort studies - PubMed | https://pubmed.ncbi.nlm.nih.gov/33469697/
Macular degeneration: peculiar sunlight exposure in an agricultural worker - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812542/
Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087473/
As a member of an elite group of only 3000 retina-vitreous specialists in the United States, Stanford trained Dr. Pilyugina brings to AGEI a unique skill set in the treatment and surgery of retinal disease. Her academic credentials include numerous research papers, conference presentations, medical publications, and clinical trials.